Healthcare & Life Sciences Private Equity Deal Tracker: H.I.G BioHealth Sells Vertiflex to Boston Scientific

McGuireWoods LLP
Contact

H.I.G. BioHealth Partners, the life-science investment affiliate of H.I.G. Capital, has announced the sale of Vertiflex to Boston Scientific. The total equity value of the sale is approximately $465 million in cash, with additional payments contingent on commercial goals.

H.I.G. BioHealth, based in Miami, invests in a broad range of healthcare opportunities, principally in companies developing therapeutic drugs, medical devices and diagnostics for unmet medical needs. The firm typically invests $5 million to $40 million per company over the life of an investment.

Vertiflex, based in Carlsbad, Calif., develops minimally invasive interventions for spinal stenosis. This includes Superion, an indirect decompression system designed to improve physical function and reduce pain in patients with lumbar spinal stenosis.

Boston Scientific (NYSE: BSX) announced its intention to acquire Vertiflex in May.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McGuireWoods LLP | Attorney Advertising

Written by:

McGuireWoods LLP
Contact
more
less

McGuireWoods LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.